Pursuant to Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 we enclose herewith the summary of the proceedings of the Extraordinary General Meeting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries held an Extraordinary General Meeting on 12th June 2025 at 3:00 p.m. via Video Conferencing, chaired by Mr. Hemal Mehta, Chairman & Managing Director. The meeting lasted about 20 minutes (ended at 3:20 p.m.). Two Special Resolutions were tabled: (1) approval to create charges, mortgages and encumbrances on company assets under Section 180(1)(a) up to Rs 2,500 Crores, and (2) authority to borrow monies under Section 180(1)(c) up to Rs 2,500 Crores. Additionally, 13 Ordinary Resolutions were placed before shareholders seeking approval for Related Party Transactions with the company's wholly-owned subsidiaries (in Singapore and India) and several related entities in the pharma/chemical space. Voting was conducted electronically, with results to be declared within 2 working days and shared with BSE and on the company's website.
The Rs 2,500 Crore borrowing and charge-creation limits represent a significant expansion of the company's financial flexibility, suggesting plans for substantial capital raising, expansion, or acquisitions. The large number of related-party transactions with subsidiaries and group entities indicates active inter-company business, which shareholders should monitor closely for pricing fairness.